PAB chart, page-1686

kev this is from a 2011 analyst report -

"Clinical Stage Projects
Patrys has three clinical stage projects.
The lead project is PAT-SM6 and there is a lot to like about it. PATSM6 has previously been shown to bind 91% of cancer tissues
tested. Preliminary results from a phase I study in melanoma patients
have demonstrated the ability of the antibody to bind tumours and
provided evidence that tumour cell death results. Patrys plans to
study PAT-SM6 in a phase I/II study in multiple myeloma patients
commencing 1HCY2012. Multiple myeloma is a high value indication
for which no antibody-based therapies have been approved and
could provide a relatively speedy route to market. Preclinical studies
have demonstrated that PAT-SM6 has significant activity against
multiple myeloma cells.
Patrys is also planning on commencing a phase I/II study of PATSM6 in solid tumours, also commencing 1HCY2012. This study will
help define follow-on indications that Patrys or a partner might wish to
pursue.
PAT-SC1 has already been shown to significantly improve survival
when used in patients with gastric cancer. Gastric cancer, however,
is primarily of interest to Asian pharmaceutical companies due to the
high incidence of the disease there. Consequently, Patrys plans to
commence a licensing campaign in that region for PAT-SC1 next
year.
Finally, Patrys is aiming to commence a phase I/II study in solid
tumours of its antibody PAT-LM1 in 2HCY2012."

I did make an inquiry of the company recently particularly in relation to PAT-SM6 and received the following reply -

"Patrys’ interest in multiple myeloma was based on the IgM antibody class that the company previously worked on.

For a range of reasons the company stopped working on IgMs in 2016, and started development of the deoxymab platform from Yale (particularly PAT-DX1).

As this stage we are focussed on solid tumours for our deoxymabs, particularly brain cancers and metastases, so multiple myeloma is not a priority indication for us."

The company outlicensed it's PAT-SC1 to a Chinese company in 2015 but we haven't had too much information on what progress they have made -